Melanotan II: Why the "Tanning Peptide" Worries Dermatologists
Tan injections promise color without the sunburn. Melanotan II has never been approved as a medicine, and dermatologists have spent fifteen years documenting why they are worried.
The pitch is seductive: a few injections and you tan deeper, burn less and skip the hours in the sun. The product behind it, melanotan II, has never been approved anywhere as a medicine, and the people who spend their working lives looking at moles have been writing warnings about it for more than fifteen years.
The short version
- Melanotan II is a synthetic peptide that activates melanocortin receptors, including the one that drives skin pigmentation. It is not FDA-approved for any use.
- It is usually bought online as a "research" powder and self-injected, often alongside sunbed or sun exposure, which is exactly the combination dermatologists worry about.
- The medical literature contains case reports of new and changing moles, melanoma diagnosed in users, and serious systemic reactions such as rhabdomyolysis. Case reports cannot prove cause, but no trial has shown it is safe.
- A different, related molecule, afamelanotide, is FDA-approved, but only for a rare light-sensitivity disorder, as a clinician-placed implant. It is not a tanning product.
- FDA's compounding advisory committee is expected to review melanotan II in early 2027. That review is not approval, and it does not make online vials legitimate.
If you have used melanotan II, or you are considering it, this article is not here to scold you. Wanting to look healthy and tanned is normal, and the online marketing is persuasive. What follows is what the product is, what has been reported, and what a sensible next step looks like, including a skin check if you have already used it. If you are curious about peptides more broadly, our peptide therapy consultations are a place to ask which ones have real evidence behind them, and which do not.
What melanotan II actually is
Your skin darkens when a hormone called alpha-melanocyte-stimulating hormone (alpha-MSH) binds the melanocortin 1 receptor on pigment cells, prompting them to make more melanin. Melanotan II is a lab-made, more stable analogue of alpha-MSH, developed at the University of Arizona in the late 1980s and 1990s while researchers explored whether stimulating pigmentation could protect skin.
The catch is that melanotan II is not selective. The melanocortin system has several receptors, and melanotan II activates more than one of them. That is why users report effects that have nothing to do with tanning: nausea, facial flushing, reduced appetite and spontaneous erections. One of those off-target effects became a drug in its own right. Bremelanotide, a closely related molecule that acts on melanocortin receptors in the brain, is FDA-approved (as Vyleesi) for a specific sexual desire disorder in premenopausal women. We cover it in our PT-141 guide.
Melanotan II itself never completed the development path. It has no approved labeling, no established dose, no manufacturing standard and no post-market safety monitoring.
How it is sold, and why that matters
Almost all melanotan II reaches consumers through websites and social media, typically as freeze-dried powder labeled "for research use only". Buyers mix it themselves and inject it under the skin, sometimes also using nasal sprays of uncertain content.
Regulators have been clear for a long time. In September 2007, FDA issued a warning letter to a US company selling melanotan II online, stating it was an unapproved drug marketed with unsupported claims, and advised consumers using it to stop and talk to a healthcare provider if they had experienced adverse effects. Regulators in other countries, including the UK and Australia, have issued similar warnings.
The "research use only" label is not a technicality. It places the product outside the pharmacy system entirely: nobody has verified what is in the vial, how much, or whether it is sterile. We explain that market in the research peptide grey market.
Be careful here
Many users take melanotan II and then "activate" the tan with sunbeds or deliberate sun exposure. Indoor tanning and sunburn are established risk factors for melanoma on their own. A product that pushes pigment cells to work harder, used alongside UV exposure, is a combination no one has studied for safety, and it is the scenario that shows up again and again in case reports.
What dermatologists have reported
There are no large controlled studies of melanotan II as it is used by the public. What exists is a trail of case reports and reviews written by clinicians who saw something unusual. Case reports are the weakest level of evidence for proving that a product caused a problem. They are, however, exactly how new safety signals first appear, and this one has been consistent.
New and changing moles
Several reports describe moles that darkened, grew or appeared in crops after melanotan II use. A 2009 report in Archives of Dermatology by Cardones and Grichnik described a man with a past melanoma and many atypical moles who self-injected a synthetic alpha-MSH peptide. He developed crops of new moles, several with atypical features under the microscope, and his existing moles darkened and grew. They lightened after he stopped. The authors concluded these peptides can drive the growth of abnormal pigment cells in predisposed people. Changing moles matter because change is one of the main warning signs dermatologists use to spot melanoma, and widespread darkening can make genuine changes harder to notice.
Melanoma in users
Dermatologists have published cases of melanoma diagnosed in people using melanotan, including a 2011 report in the British Journal of Dermatology by Paurobally and colleagues, and a 2014 case in Dermatology by Hjuler and Lorentzen describing melanoma in a young woman who had used melanotan II together with sunbeds. The authors of that report noted that because the drug is unlicensed and incompletely tested, the extent and types of its adverse effects are unknown. None of these reports proves melanotan II caused the cancer; UV exposure and individual risk were also present. But none offers any reassurance either.
Serious reactions beyond the skin
Emergency and toxicology journals have reported systemic problems after injections. A 2012 case in Clinical Toxicology described systemic toxicity and rhabdomyolysis, a breakdown of muscle tissue that can damage the kidneys, after melanotan II injection. A 2013 report in the same journal described priapism, a prolonged painful erection that is a urological emergency, associated with a melanotan II overdose. A 2017 review in the International Journal of Dermatology by Habbema and colleagues gathered the reported risks of unregulated melanocortin analogue use and called for better public awareness.
Worth knowing
Because melanotan II is bought outside the pharmacy system, it is often impossible to know whether a reaction came from the peptide, from a contaminant, from the wrong amount, or from a non-sterile injection. That uncertainty is itself one of the risks.
The approved cousin that gets misused in marketing
Sellers sometimes point to afamelanotide as proof that "tanning peptides are FDA-approved". That is misleading.
Afamelanotide is a different alpha-MSH analogue, and it acts more selectively on the pigmentation receptor. In October 2019 FDA approved it, under the brand name Scenesse, for adults with erythropoietic protoporphyria, a rare genetic condition in which light exposure causes severe pain. It is given as a small implant placed under the skin by a trained healthcare professional, and its labeling includes regular full-body skin examinations. It is not approved for cosmetic tanning, and its approval says nothing about the safety of melanotan II.
Where melanotan II stands with regulators
Melanotan II has no FDA approval for any use. It has also been part of the long-running question of which peptides compounding pharmacies may use as bulk ingredients. A further review by FDA's Pharmacy Compounding Advisory Committee, covering melanotan II alongside several other peptides, is expected in February 2027.
Two points about that are easy to lose in online coverage. An advisory committee vote is non-binding; adding a substance to the list pharmacies may compound from requires FDA rulemaking afterward. And even a favorable outcome would not make it FDA-approved, would not validate tanning claims, and would do nothing to regulate vials sold online as research chemicals. We walk through how this process works in the July 2026 FDA peptide vote, explained. Rules change, so verify the current position with FDA before relying on anything here.
If you have already used melanotan II
Stopping is the first step. After that:
- Book a full skin examination with a dermatologist, and tell them you used melanotan II and roughly when. That history changes how they assess your moles.
- Watch for changes in the size, shape, color or border of any mole, a new mole that looks different from your others, or one that itches or bleeds. Report these promptly rather than waiting for a routine visit.
- Seek urgent care for an erection lasting more than four hours, severe muscle pain with dark urine, chest pain, or a racing heart after an injection.
- Report adverse effects to FDA's MedWatch program. Reports about unregulated products help regulators see patterns.
If what you really want is an honest conversation about skin, sexual health or appearance goals, including which approved options exist and which marketing claims to ignore, you can book a consultation with one of our clinicians. We will not prescribe melanotan II, and we will tell you plainly if nothing we offer is the right fit.
Common questions
Is melanotan II legal in the US?
It is not FDA-approved, and FDA has taken action against companies selling it for human use. Products sold online as "research chemicals" are outside the regulated drug system. Legal availability through compounding pharmacies has not been established; check FDA's current position.
Does melanotan II cause skin cancer?
That has not been proven or disproven, because the controlled studies have not been done. Dermatologists have published cases of melanoma and changing moles in users, often alongside UV exposure, which is enough for many to advise against it.
Is a melanotan tan protective against sunburn?
Do not rely on it. There is no approved product or labeling that supports melanotan II as sun protection, and FDA's 2007 action specifically cited unsupported skin cancer protection claims. Sunscreen, shade and clothing remain the evidence-based approach.
Is melanotan II the same as PT-141?
No. They are related molecules, but bremelanotide (PT-141) is an FDA-approved medicine for a specific indication, with defined labeling and known side effects. Melanotan II has neither.
What about nasal tanning sprays?
Nasal products sold online for tanning face the same problems as injectable ones, with an added uncertainty about how much, if any, active ingredient is absorbed. They are not approved.
Talk to a licensed clinician
Reading about a treatment is not the same as knowing whether it fits your history. A consultation is a conversation about your own situation — not a sales call, and not a promise of any outcome.
Book a consultation
